title: Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
abstract: The transcription factor Nrf2 is a master regulator of cellular defence: Nrf2 null mice (Nrf2((-/-))) are highly susceptible to chemically induced toxicities. We report a comparative iTRAQ-based study in Nrf2((-/-)) mice treated with a potent inducer, methyl-2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate (CDDO-me; bardoxolone -methyl), to define both the Nrf2-dependent basal and inducible hepatoproteomes. One thousand five hundred twenty-one proteins were fully quantified (FDR <1%). One hundred sixty-one were significantly different (P<0.05) between WT and Nrf2((-/-)) mice, confirming extensive constitutive regulation by Nrf2. Treatment with CDDO-me (3mg/kg; i.p.) resulted in significantly altered expression of 43 proteins at 24h in WT animals. Six proteins were regulated at both basal and inducible levels exhibiting the largest dynamic range of Nrf2 regulation: cytochrome P4502A5 (CYP2A5; 17.2-fold), glutathione-S-transferase-Mu 3 (GSTM3; 6.4-fold), glutathione-S-transferase Mu 1 (GSTM1; 5.9-fold), ectonucleoside-triphosphate diphosphohydrolase (ENTPD5; 4.6-fold), UDP-glucose-6-dehydrogenase (UDPGDH; 4.1-fold) and epoxide hydrolase (EPHX1; 3.0-fold). These proteins, or their products, thus provide a potential source of biomarkers for Nrf2 activity. ENTPD5 is of interest due to its emerging role in AKT signalling and, to our knowledge, this protein has not been previously shown to be Nrf2-dependent. Only two proteins altered by CDDO-me in WT animals were similarly affected in Nrf2((-/-)) mice, demonstrating the high degree of selectivity of CDDO-me for the Nrf2:Keap1 signalling pathway.
  
  
  CONCLUSIONS
  The Nrf2:Keap1 signalling pathway is attracting considerable interest as a therapeutic target for different disease conditions. For example, CDDO-me (bardoxolone methyl) was investigated in clinical trials for the treatment of acute kidney disease, and dimethyl fumarate, recently approved for reducing relapse rate in multiple sclerosis, is a potent Nrf2 inducer. Such compounds have been suggested to act through multiple mechanisms; therefore, it is important to define the selectivity of Nrf2 inducers to assess the potential for off-target effects that may lead to adverse drug reactions, and to provide biomarkers with which to assess therapeutic efficacy. Whilst there is considerable information on the global action of such inducers at the mRNA level, this is the first study to catalogue the hepatic protein expression profile following acute exposure to CDDO-me in mice. At a dose shown to evoke maximal Nrf2 induction in the liver, CDDO-me appeared highly selective for known Nrf2-regulated proteins. Using the transgenic Nrf2((-/-)) mouse model, it could be shown that 97% of proteins induced in wild type mice were associated with a functioning Nrf2 signalling pathway. This analysis allowed us to identify a panel of proteins that were regulated both basally and following Nrf2 induction. Identification of these proteins, which display a large magnitude of variation in their expression, provides a rich source of potential biomarkers for Nrf2 activity for use in experimental animals, and which may be translatable to man to define individual susceptibility to chemical stress, including that associated with drugs, and also to monitor the pharmacological response to Nrf2 inducers.
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: joanne.henry@liv.ac.uk.
authors.forename: Joanne
authors.initials: J
authors.lastname: Walsh
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: rjenkins@liv.ac.uk.
authors.forename: Rosalind E
authors.initials: RE
authors.lastname: Jenkins
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: cc0u5137@liverpool.ac.uk.
authors.forename: Michael
authors.initials: M
authors.lastname: Wong
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: a.olayanju@liv.ac.uk.
authors.forename: Adedamola
authors.initials: A
authors.lastname: Olayanju
authors.affiliation: AstraZeneca R&D Alderley Park, Safety Assessment UK, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom. Electronic address: Helen.powell2@astrazeneca.com.
authors.forename: Helen
authors.initials: H
authors.lastname: Powell
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: icopple@liv.ac.uk.
authors.forename: Ian
authors.initials: I
authors.lastname: Copple
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: pmoneill@liv.ac.uk.
authors.forename: Paul M
authors.initials: PM
authors.lastname: O'Neill
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: chrissy@liv.ac.uk.
authors.forename: Christopher E P
authors.initials: CE
authors.lastname: Goldring
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: neilk@liv.ac.uk.
authors.forename: Neil R
authors.initials: NR
authors.lastname: Kitteringham
authors.affiliation: MRC Centre for Drug Safety Science, School of Biomedical Sciences, University of Liverpool, Sherrington Buildings, Liverpool, Merseyside L69 3GE, United Kingdom. Electronic address: bkpark@liv.ac.uk.
authors.forename: B Kevin
authors.initials: BK
authors.lastname: Park
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D000818:Animals; D003598:Cytoskeletal Proteins / Q000235:genetics / Q000378:metabolism; D005260:Female; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D000072019:Kelch-Like ECH-Associated Protein 1; D008099:Liver; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D051267:NF-E2-Related Factor 2 / Q000235:genetics / Q000378:metabolism*; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D010088:Oxidoreductases / Q000096:biosynthesis / Q000235:genetics; D020543:Proteome / Q000096:biosynthesis* / Q000235:genetics; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D003598:Cytoskeletal Proteins; C117301:Keap1 protein, mouse; D000072019:Kelch-Like ECH-Associated Protein 1; D051267:NF-E2-Related Factor 2; C495636:Nfe2l2 protein, mouse; D020543:Proteome; D009828:Oleanolic Acid; C445068:bardoxolone methyl; D010088:Oxidoreductases; D051057:Proto-Oncogene Proteins c-akt
keywords: CDDO; CYP2A5; ENTPD5; Hepatoproteome; Nrf2; iTRAQ